USA flag logo/image

An Official Website of the United States Government

Lightweight Electronically Controlled Transdermal Patch for Enfuvirtide Delivery

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93364
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AI080335
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Actuated Medical, Inc.
310 Rolling Ridge Drive Bellefonte, PA 16823-8445
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Lightweight Electronically Controlled Transdermal Patch for Enfuvirtide Delivery
Agency: HHS
Contract: 1R43AI080335-01A1
Award Amount: $99,997.00
 

Abstract:

DESCRIPTION (provided by applicant): This Phase I NIH SBIR, will develop a Lightweight Electronically Controlled Transdermal Patch for Enfuvirtide Delivery (LET-PED). Thirty-three million people worldwide are living with the Human Immunodeficiency Virus (H IV). Currently, patients infected with HIV receive Highly Active Antiretroviral Therapy (HAART) for the management of the infection. HAART regimens can be complex in terms of numbers of medications, number of doses per day, and adverse effects. Medication regimens for the management of HIV must be taken with near perfect compliance to maximize benefits and prevent the development of viral resistance. Enfuvirtide, approved by the Food and Drug Administration (FDA) in 2003, is an infusion inhibitor that block s the HIV from attaching to the CD4 cell (or T-cell). It is subcutaneously injected twice daily and directed at patients not responding to other treatments. However, it has been found that 98% of patients experience injection site reactions. Piezoelectric ultrasonic transdermal drug delivery technologies have been shown to delivery insulin in animal models and human trials. The 20 kHz ultrasonic waves open 25 to 125 m micro-channels in the stratum corneum, allowing the medications to reach the blood system , but operate at low intensity levels that did not show any noticeable damage or significant skin change using histological examination. The LET-PED will be a needle-free, automatic and safe ultrasonic drug delivery device to keep HIV patients in medicatio n regime compliance. Phase I Specific Aims are: 1. Design and build a piezoelectric lightweight transducer drug delivery patch with a replaceable/refillable drug reservoir and piezoelectric micro-pump. 2. Characterize the acoustic energy field and determin e the safety limits to skin with histological and confocal microscopy studies 3. Perform acoustic experiments using human skin samples with Enfuvirtide to evaluate the penetration using the LET-PED These aims will test the hypothesis that that a piezoelect ric transdermal drug delivery patch can allow Enfuviritide to pass through the skin without causing tissue damage. The long-term objective of this work is to commercialize the LET-PED. The HIV population of ~2 million patients in Western Europe and North A merica would be the first target market. The technology could also be licensed for specific application areas. PUBLIC HEALTH RELEVANCE: This Phase I NIH SBIR, will develop a Lightweight Electronically Controlled Transdermal Patch for Enfuvirtide Delivery. The LET-PED will be a needle- free, automatic and safe ultrasonic drug delivery device to keep HIV patients in medication regime compliance.

Principal Investigator:

Maureen L. Mulvihill
8143550003
MMULVIHILL@PIEZO-RES.COM

Business Contact:

Maureen L. Mulvihill
mmulvihill@piezo-res.com
Small Business Information at Submission:

PIEZO RESONANCE INNOVATIONS, INC.
PIEZO RESONANCE INNOVATIONS, INC. 310 Rolling Ridge Dr Bellefonte, PA 16823

EIN/Tax ID: 208111286
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No